The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

Snack foods and sweet treats have seen a decline in purchases, as people reach for more nutrient-dense options.

If your constipation lasts for more than three days, speak with your doctor about options to help. You might need to add a ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Drugs like Ozempic and Wegovy were already off to fast starts because of their ability to help treat Type 2 diabetes and ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

GLP-1, or glucagon-like peptide-1, is a hormone produced in the digestive system that regulates appetite and insulin secretion. Medications like Ozempic and Wegovy, categorized as GLP-1 agonists ...